Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma. - Phase II study of VI / VPC / IE / VAC for patients with newly diagnosed high-risk rhabdomyosarcoma.

Japan Children's Cancer Group (JCCG)0 个研究点目标入组 60 人开始时间: 2017年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) primary central nervous system rhabdomyosarcoma, positive findings of cerebrospinal fluid cytology, metastatic central nervous system rhabdomyosarcoma 2) patients with synchronous or metachronous concomitant malignancies 3) patients with Charcot-Marie-Tooth disease or varicella 4) patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 5) patients with contraindication of drugs used in this study 6) Female patients who are pregnant or breastfeeding mother or patients considering pregnancy 7) Patients with any other inappropriate condition judged by physician

发起方

Japan Children's Cancer Group (JCCG)